Your browser doesn't support javascript.
loading
Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina; Chen, Baoqing; Redis, Roxana; Fabris, Linda; Zhang, Xinna; Ivan, Cristina; Shimizu, Masayoshi; Rodriguez-Aguayo, Cristian; Dragomir, Mihnea; Van Roosbroeck, Katrien; Almeida, Maria Ines; Ciccone, Maria; Nedelcu, Daniela; Cortez, Maria Angelica; Manshouri, Taghi; Calin, Steliana; Muftuoglu, Muharrem; Banerjee, Pinaki P; Badiwi, Mustafa H; Parker-Thornburg, Jan; Multani, Asha; Welsh, James William; Estecio, Marcos Roberto; Ling, Hui; Tomuleasa, Ciprian; Dima, Delia; Yang, Hui; Alvarez, Hector; You, M James; Radovich, Milan; Shpall, Elizabeth; Fabbri, Muller; Rezvani, Katy; Girnita, Leonard; Berindan-Neagoe, Ioana; Maitra, Anirban; Verstovsek, Srdan; Fodde, Riccardo; Bueso-Ramos, Carlos; Gagea, Mihai; Manero, Guillermo Garcia; Calin, George A.
Afiliação
  • Shah MY; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Ferracin M; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40126 Bologna, Italy.
  • Pileczki V; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Chen B; The Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj Napoca, Romania.
  • Redis R; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Fabris L; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Zhang X; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Ivan C; Center for RNA Interference and Non-coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Shimizu M; Center for RNA Interference and Non-coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Rodriguez-Aguayo C; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Dragomir M; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Van Roosbroeck K; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Almeida MI; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Ciccone M; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Nedelcu D; Institute for Research and Innovation in Health (I3S), and Institute of Biomedical Engineering (INEB), University of Porto, 4200-135, Porto, Portugal.
  • Cortez MA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Manshouri T; Hematology Section, Azienda Ospedaliero-Universitaria Arcispedale S. Anna, 44124, Ferrara, Italy.
  • Calin S; Department of Oncology-Pathology, Karolinska Institute, Cancer Center Karolinska, SE-171 77 Stockholm, Sweden.
  • Muftuoglu M; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Banerjee PP; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Badiwi MH; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Parker-Thornburg J; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Multani A; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Welsh JW; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Estecio MR; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Ling H; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Tomuleasa C; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Dima D; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Yang H; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Alvarez H; The Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj Napoca, Romania.
  • You MJ; Department of Hematology, The Oncology Institute Ion Chiricuta, 400015 Cluj Napoca, Romania.
  • Radovich M; Department of Hematology, The Oncology Institute Ion Chiricuta, 400015 Cluj Napoca, Romania.
  • Shpall E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Fabbri M; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Rezvani K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Girnita L; Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.
  • Berindan-Neagoe I; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Maitra A; Departments of Pediatrics and Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Children's Center for Cancer and Blood Diseases and The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, Califor
  • Verstovsek S; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Fodde R; Department of Oncology-Pathology, Karolinska Institute, Cancer Center Karolinska, SE-171 77 Stockholm, Sweden.
  • Bueso-Ramos C; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Gagea M; The Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj Napoca, Romania.
  • Manero GG; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
  • Calin GA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
Genome Res ; 28(4): 432-447, 2018 04.
Article em En | MEDLINE | ID: mdl-29567676
ABSTRACT
The cancer-risk-associated rs6983267 single nucleotide polymorphism (SNP) and the accompanying long noncoding RNA CCAT2 in the highly amplified 8q24.21 region have been implicated in cancer predisposition, although causality has not been established. Here, using allele-specific CCAT2 transgenic mice, we demonstrate that CCAT2 overexpression leads to spontaneous myeloid malignancies. We further identified that CCAT2 is overexpressed in bone marrow and peripheral blood of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) patients. CCAT2 induces global deregulation of gene expression by down-regulating EZH2 in vitro and in vivo in an allele-specific manner. We also identified a novel non-APOBEC, non-ADAR, RNA editing at the SNP locus in MDS/MPN patients and CCAT2-transgenic mice. The RNA transcribed from the SNP locus in malignant hematopoietic cells have different allelic composition from the corresponding genomic DNA, a phenomenon rarely observed in normal cells. Our findings provide fundamental insights into the functional role of rs6983267 SNP and CCAT2 in myeloid malignancies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proliferação de Células / Doenças Mieloproliferativas-Mielodisplásicas / RNA Longo não Codificante Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proliferação de Células / Doenças Mieloproliferativas-Mielodisplásicas / RNA Longo não Codificante Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article